LLY and HIMS Related Headlines
Go Back- FDA issues 30 warning letters to telehealth firms over GLP-1 claims
- Hims and Hers (HIMS) PT Lowered to $20 at Leerink Partners
- Novo Nordisk jumps, Hims shares plummet after pulling $49 weight-loss pill
- FDA moves to restrict copycat GLP-1 weight loss drugs
- TD Cowen Reiterates Hold Rating on Hims and Hers (HIMS)
- Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'
- Leerink: 'there is no reason why HIMS shouldn't evaluate these launches for every subsequent weight loss product'
- Wolfe Research on Eli Lilly (LLY): 'we question the legality of HIMS' ability to market an oral semaglutide'
- Wells Fargo on Eli Lilly (LLY): 'Compounders Strike Again, but We See Little Risk to Near-Term Growth'
- Hims stock surges as Wegovy pill copy offered at $49, Novo shares fall
- Hims stock falls after lawmakers propose GLP-1 compounding restrictions
- Novo Nordisk cuts cash prices for Wegovy and Ozempic to $199 monthly
- Walmart (WMT) Adds Home Delivery for Ozempic, Other Refrigerated Drugs - Bloomberg
- U.S. FDA sends drug advertising warning letters to Lilly, Novo, Hims
- BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $28
- Hims&Hers gains after court rejects Eli Lilly’s case against Willow
- Eli Lilly stock rises, Novo Nordisk shares jump on potential Medicare coverage
- Hims & Hers (HIMS) reportedly makes statement on congressional letter to FDA
- Hims & Hers Health, Inc. (NYSE: HIMS) Falls, Group Of 81 Bipartisan Lawmakers Sign Letter On Glp-1 Action
- Morgan Stanley on Compounder Lawsuits: 'experts think the courts would likely refuse to dismiss the case and that it could take 2-3 years to resolve'
- Citi on Hims and Hers (HIMS): 'If HIMS does end up partnering with LLY, in our view it would signal that HIMS is “throwing in the towel” on compounded GLP-1s'
- Hims&Hers stock falls after Lilly rules out partnership
